ArticleCureus2025
Fatty Liver Disease in the Diabetic Population: A Cross-Sectional Study From Pakistan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disorder, particularly among patients with type 2 diabetes mellitus (T2DM). The association between NAFLD and diabetes is bidirectional, with NAFLD increasing the risk of diabetes and vice versa. Therefore, this study aimed to determine the prevalence of NAFLD in diabetic individuals and evaluate the impact of metabolic and cardiovascular factors, along with the role of anti-diabetic medications in NAFLD progression. Study methodology After the approval from the United Medical and Dental College - Institutional Review Board (UMDC-IRB) (UMDC-IRB-2022/A-1713), this cross-sectional study was carried out at the Department of Gastroenterology, United Medical and Dental College from January 2023 to December 2023. A total of 250 diabetic patients aged between 30 and 65 years were enrolled in the study. Patients with a history of alcohol consumption, viral hepatitis, autoimmune hepatitis, and chronic kidney disease (CKD) stage 4 or higher were excluded from the study. Data collection involved demographic profiling, laboratory investigations (HbA1c, lipid profile, and liver function tests), and imaging assessment using an abdominal ultrasound to determine the presence or absence of fatty liver. Statistical analysis was conducted using SPSS version 25.0 (IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY), with p ≤ 0.05 considered statistically significant. Results Among the 250 diabetic patients, 178 (71.2%) were diagnosed with NAFLD. Higher BMI (p ≤ 0.001), poor glycemic control (HbA1c > 8.5%) (p ≤ 0.001), and dyslipidemia (p ≤ 0.001) were significantly associated with the presence of NAFLD in the diabetic population. Hypertension (p ≤ 0.001) and coronary artery disease (p = 0.031) were also the factors more prevalent in the NAFLD group. Patients on glucagon-like peptide 1 (GLP-1) receptor agonists (p = 0.018) and sodium-glucose cotransporter-2 (SGLT2) inhibitors (p = 0.042) had a significantly lower prevalence of NAFLD. Conclusion NAFLD is highly prevalent among diabetic individuals, with significant cardiovascular implications. Routine screening and targeted interventions are essential to mitigate liver-related complications in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.